Data integrity & provenance
Audit source cohorts, identify overlap and leakage, evaluate missingness, and verify that training and validation populations are truly independent.
Healthcare analytics · Predictive intelligence
From healthcare data to decisions that matter.
We build interpretable, rigorously validated machine-learning solutions that help healthcare leaders identify risk, focus resources, and turn complex data into actionable intelligence.
What we deliver
End-to-end predictive AI, grounded in real healthcare data.
Model development is only one part of the work. Reliable healthcare AI demands trustworthy data, credible validation, transparent interpretation, and a clear operational use case.
Predictive modeling
Develop and compare statistical and machine-learning models using defensible cross-validation and carefully controlled tuning.
External validation
Test generalization across different patient populations, outcome prevalences, and clinical environments.
Explainable AI
Use feature-level interpretation, including SHAP, to understand what drives model scores and investigate unexpected patterns.
Risk prioritization
Translate model outputs into practical targeting strategies, including high-risk segments, event capture, and cumulative lift.
Responsible deployment
Evaluate calibration, population drift, fairness considerations, and the limits of what a model can reliably claim.
Featured analytical case study
Development and External Validation of a Machine-Learning Model for Prospective Healthcare Risk Stratification
A complete modeling workflow—from discovering hidden cohort overlap to demonstrating meaningful risk concentration in an independent healthcare population.
19,809Patients in external validation
0.829External AUROC
5.31×AUPRC relative to prevalence baseline
147Predictors retained after audit
The executive takeaway
Focus attention where the events are concentrated.
In an independent validation cohort, the model ranked patients by their relative likelihood of the target outcome. The top-scoring 10% of patients accounted for nearly half of all observed events.
For a resource-constrained care-management or population-health program, this illustrates the potential value of using predictive intelligence to prioritize outreach and evaluation. The analysis demonstrates targeting performance—not a measured reduction in events or a proven intervention benefit.
Important distinction: These are relative risk rankings, not calibrated absolute probabilities. The model's raw probability outputs require additional population-appropriate calibration before being used as individual event-risk estimates.
How much risk is concentrated?
Share of observed events captured in external validation
Observed outcomes in Dataset C (n = 19,809; 814 events; 4.11% prevalence). Bars represent cumulative capture, not predicted probability.
Why this case study matters
Rigor behind the headline metrics.
Audit the cohorts
Found 3,000 overlapping records between development Dataset A and proposed test Dataset B—an issue that could otherwise inflate performance.
Protect independent testing
Excluded the overlapping dataset and reserved Dataset C for external validation, with no exact feature-level overlap with A.
Build and compare
Evaluated logistic regression and XGBoost with stratified cross-validation and out-of-fold predictions.
Validate transportability
Achieved external AUROC of 0.829 versus internal out-of-fold AUROC of 0.850 despite substantial population differences.
Explain the predictions
Used SHAP to identify major drivers, including age, chronic conditions, medication burden, prior utilization and healthcare engagement.
Challenge assumptions
Detected an unusual pediatric sampling pattern and assessed an adult-only model as a clearly labeled post-hoc sensitivity analysis.
Analytical results
Discrimination is strong. Calibration needs work.
The XGBoost model achieved an external AUROC of 0.8293 and AUPRC of 0.2183, compared with a 4.11% outcome prevalence. An adult-only sensitivity analysis yielded similar results (AUROC 0.8312; AUPRC 0.2252).
However, the balanced training sample led to materially overstated absolute probabilities in the lower-prevalence external cohort. That finding is central to the study: strong ranking ability does not automatically make a model ready to report individual clinical probabilities.
What responsible AI looks like in practice
We do not stop at an impressive accuracy statistic. We test whether the data are independent, whether patterns generalize, whether model scores can be interpreted safely, and whether the output matches the decision a healthcare organization actually needs to make.
Research transparency
What the example demonstrates—and what it does not.
This is a methodological case study using three healthcare datasets. The exact original clinical definition and prediction horizon of the variable FINAL_OUTCOME have not yet been verified, so the outcome is intentionally described generically. The model has not been presented here as a deployed clinical tool, and no intervention effectiveness is claimed.
The adult-only model was examined after the primary external evaluation and is a post-hoc sensitivity analysis—not a second untouched external validation. Before operational deployment, additional work would include formal target-definition confirmation, representative probability calibration, subgroup/fairness assessment, and prospective validation.
Let's make healthcare data actionable
Have a healthcare prediction challenge?
From exploratory cohort analysis to externally validated risk models and executive decision tools, CALIBER360 AI Solutions can help connect advanced analytics with practical strategy.
Start a conversation